MDxHealth, Merck KGaA Extend Deal for Cancer Trial

Merck will continue use of MDxHealth's MGMT assay in a clinical trial for its integrin inhibitor cilengitide for patients with glioblastoma with a methylated promoter of the MGMT gene.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.